Growing the pipeline, growing the bottom line — shifts in pharmaceutical R&D innovation
By Chris Stirling
As spending on pharmaceutical research and development (R&D) continues to soar, executives, shareholders and analysts alike are entitled to ask: what value are we getting for our investment?
The pharma sector invests more money in research than any other industry, with five of the world’s 10 highest R&D budgets belonging to drug companies. Between 2004 and 2013, the total industry expenditure on R&D rose from $88bn (£52bn) to $135bn, and is forecast to reach $149bn by 2018.
Yet in the same time period, the estimated cost of bringing a new chemical or biological product to market has more than trebled from $451m to $1.5bn. Meanwhile, the average number of annual US Food and Drug Administration (FDA) approvals for new molecular entities (NMEs) — a good directional indicator of innovation — fell from 31.5 in 1990 to an average of just 22.9 from 2001–10…
Click on the link below to read the rest of the KPMG briefing.
News from KPMG
News from The Lawyer
Briefings from KPMG
The role of business is increasingly being scrutinised, debated and challenged. As a business community, we need to be aware of this trend and respond to it.
The Nigerian banking landscape continues to face significant headwinds on its bottom line — both from the top line and costs.